Use the tools below to get more information about INTRAROSA, and help patients understand their condition and start treatment with INTRAROSA.

For your patients

Condition Discussion Guide
Download this tool to help your patients get the conversation started about their pain
Download Guide
INTRAROSA Patient Copay Savings Card
Help your patients save with the INTRAROSA patient copay savings card
Download Information

For your practice

Interactive PI
Download an easy-to-navigate interactive PI
Download Interactive PI
Sample Request Form
Download and complete a sample request form to receive your INTRAROSA samples. Limitations apply
Download Form
See More


INTRAROSA is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

Important Safety Information

INTRAROSA is contraindicated in women with undiagnosed abnormal genital bleeding.

Estrogen is a metabolite of prasterone. Use of exogenous estrogen is contraindicated in women with a known or suspected history of breast cancer. INTRAROSA has not been studied in women with a history of breast cancer.

In four 12-week randomized, placebo-controlled clinical trials, the most common adverse reaction with an incidence ≥2 percent was vaginal discharge. In one 52-week open-label clinical trial, the most common adverse reactions with an incidence ≥2 percent were vaginal discharge and abnormal Pap smear.

To report SUSPECTED ADVERSE REACTIONS, contact AMAG Pharmaceuticals at 1­-877-411-2510 or FDA at 1-800­-FDA-1088 or

Please see full Prescribing Information.